Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

R9281

Sigma-Aldrich

Rotigotine hydrochloride

≥98% (HPLC)

Synonym(s):

(−)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol hydrochloride, (−)-N 0437, N 0923, Neupro, SPM 962

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C19H25NOS·HCl
CAS Number:
125572-93-2
Molecular Weight:
351.93
MDL number:
MFCD00906149
UNSPSC Code:
12352200
PubChem Substance ID:
329824046
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

solid

storage condition

desiccated

color

white to off-white

solubility

DMSO: >10 mg/mL

originator

UCB Inc.

storage temp.

room temp

SMILES string

Cl.CCCN(CCc1cccs1)[C@H]2CCc3c(O)cccc3C2

InChI

1S/C19H25NOS.ClH/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21;/h3-7,13,16,21H,2,8-12,14H2,1H3;1H/t16-;/m0./s1

InChI key

CEXBONHIOKGWNU-NTISSMGPSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Rotigotine hydrochloride is a non-ergolinic D3/D2 and D1-dopamine agonist. It is appropriate for transdermal delivery through skin patches, that has the drug in a silicone-based adhesive matrix.
Rotigotine is a dopamine receptor agonist with preference for D3 receptors over D2 and D1. As such, it is an effective anti-Parkinsonian agent. Racemic rotigotine is about 50 times as potent as quinpirole, the gold standard D2 agonist.

Features and Benefits

This compound was developed by UCB Inc.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Naoki Adachi et al.
Neuroscience letters, 662, 44-50 (2017-10-11)
Brain-derived neurotrophic factor (BDNF) critically controls the fate and function of the neuronal network and has received much attention as a target of many brain diseases. Dopaminergic system dysfunction has also been implicated in a variety of neuropsychiatric diseases. Rotigotine
Elisabeth Dohin et al.
Expert opinion on pharmacotherapy, 14(1), 15-25 (2012-12-22)
This post-hoc analysis of a prospective open-label study investigated patients with restless legs syndrome (RLS) taking approved dosages (1, 2 or 3 mg/24 h) of rotigotine transdermal patch for up to 5 years. Following 6 weeks' double-blind treatment, patients with
Andres Ceballos-Baumann et al.
Current medical research and opinion, 27(10), 1899-1905 (2011-08-27)
The dopamine agonist rotigotine has shown efficacy and safety for the treatment of early and advanced Parkinson's disease (PD) in controlled clinical trials. This observational study evaluated rotigotine administration in combination with other antiparkinsonian medication in routine clinical practice. Data
Wolfgang Oertel et al.
Parkinsonism & related disorders, 19(1), 37-42 (2012-09-08)
Although dopamine agonists (DAs) are sometimes perceived as poorly tolerated by the elderly, there is little clinical evidence to support these concerns. Safety and tolerability of rotigotine have been demonstrated in four 6-month randomized placebo-controlled studies: two in early Parkinson's
In brief: transdermal rotigotine (Neupro).
The Medical letter on drugs and therapeutics, 54(1397), 68-68 (2012-08-22)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service